A Phase 2 Open-Label Study of the Efficacy of ABT-199 (GDC-0199) in Subjects With Relapsed/Refractory or Previously Untreated Chronic Lymphocytic Leukemia Harboring the 17p Deletion

Trial Profile

A Phase 2 Open-Label Study of the Efficacy of ABT-199 (GDC-0199) in Subjects With Relapsed/Refractory or Previously Untreated Chronic Lymphocytic Leukemia Harboring the 17p Deletion

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 12 Jun 2018

At a glance

  • Drugs Venetoclax (Primary)
  • Indications Chronic lymphocytic leukaemia
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Sponsors AbbVie
  • Most Recent Events

    • 12 Jun 2018 Results (n=350) of an integrated safety analysis (data cutoff date: 28 Nov 2016) of Venetoclax monotherapy in patients with relapsed/refractory chronic lymphocytic leukemia using dataset from three phase-I/II studies (NCT01328626, NCT01889186 and NCT02141282) published in the Clinical Cancer Research Journal.
    • 05 Jun 2018 Results presented at the 54th Annual Meeting of the American Society of Clinical Oncology
    • 01 May 2018 Results (Data cut off April 4, 2017) from full population assessing safety and efficacy published in the Journal of Clinical Oncology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top